Ascelia Pharma AB (publ) (ACE) - Total Liabilities

Latest as of September 2025: Skr22.01 Million SEK ≈ $2.37 Million USD

Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has total liabilities worth Skr22.01 Million SEK (≈ $2.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Ascelia Pharma AB (publ) to assess how effectively this company generates cash.

Ascelia Pharma AB (publ) - Total Liabilities Trend (2016–2024)

This chart illustrates how Ascelia Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Ascelia Pharma AB (publ)'s assets to evaluate the company's liquid asset resilience ratio.

Ascelia Pharma AB (publ) Competitors by Total Liabilities

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
Firetail Resources Ltd AU:FTL	Australia	AU$958.84K
DT Cloud Star Acquisition Corporation Ordinary Shares NASDAQ:DTSQ	USA	$795.62K
Ajinextek Co. Ltd KQ:059120	Korea	₩4.25 Billion
Jindalee Lithium Ltd AU:JLL	Australia	AU$3.86 Million
ROK Resources Inc V:ROK	Canada	CA$41.84 Million
SIFCO Industries Inc NYSE MKT:SIF	USA	$36.24 Million
Honmyue Enterprise Co Ltd TW:1474	Taiwan	NT$1.54 Billion
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA F:MUT3	Germany	€69.33 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Ascelia Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACE market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.60	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.19	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.16	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascelia Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascelia Pharma AB (publ) (2016–2024)

The table below shows the annual total liabilities of Ascelia Pharma AB (publ) from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr61.98 Million ≈ $6.67 Million	+386.32%
2023-12-31	Skr12.74 Million ≈ $1.37 Million	-66.21%
2022-12-31	Skr37.71 Million ≈ $4.06 Million	+46.97%
2021-12-31	Skr25.66 Million ≈ $2.76 Million	+32.82%
2020-12-31	Skr19.32 Million ≈ $2.08 Million	+46.75%
2019-12-31	Skr13.16 Million ≈ $1.42 Million	+16.03%
2018-12-31	Skr11.35 Million ≈ $1.22 Million	+156.73%
2017-12-31	Skr4.42 Million ≈ $475.55K	+58.33%
2016-12-31	Skr2.79 Million ≈ $300.36K	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$40.96 Million

Skr380.61 Million SEK

Market Cap Rank

#22609 Global

#421 in Sweden

Share Price

Skr3.00

Change (1 day)

+2.04%

52-Week Range

Skr2.60 - Skr5.10

All Time High

Skr900.24